|
SI2C 2012 Midyear Announcement
HSINCHU, TAIWAN--(Marketwire - Jun 17, 2012) - In early June, Taiwan Supra Integration and Incubation Center (SI2C) had their first new drug portfolio advisory group (NDPAG) meeting to discuss progress on the mapping and capability building of R and D drug discovery and development as well as review of opportunities and technologies proposed by the work group for full due diligence. The advisory group endorsed value chain mapping of lung cancer, liver cancer, and TB/MDR-TB, with suggestions on steps to further strengthen Taiwan capability to discover and develop new drugs against these diseases of high medical need in Taiwan, China, and other Asia-Pacific countries. Among seven opportunities reviewed for entering full due-diligence step for incubation and seed funding, one project was approved by the advisory group.
View More : http://www.marketwire.com/mw/release.do?id=1670206&sourceType=3
|
|
|